Advertisement

Local Adjuvant Adoptive Immunotherapy of Patients with Malignant Gliomas

  • F. Weber
  • A. Klein-Struckmeyer
  • J. Menzel
  • U. Pohl
Conference paper
Part of the Advances in Neurosurgery book series (NEURO, volume 20)

Abstract

During the past years immunotherapy of patients with malignant brain tumors using biological response modifiers (BRM) such as interferons and interleukin-2 has become an area of increasing interest. The current therapeutic concept consists primarily of surgery which is supported by adjuvant modalities such as radiation therapy and/or chemotherapy. Knowing that the brain is an “immunoprivileged” organ, it would be favorable to modulate the natural immunity in such a way as to rebuild the immune surveillance.

Keywords

Malignant Glioma Brain Edema Glioblastoma Multiforme Malignant Brain Tumor Biological Response Modifier 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barba D, Saris ST, Holder C, Rosenberg ST, Oldfield EH (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175–182PubMedCrossRefGoogle Scholar
  2. 2.
    Ingram M, Shelden CH, Jacques S (1987) Preliminary clinical trial of immunotherapy for malignant glioma. J Biol Response Mod 6:489–498PubMedGoogle Scholar
  3. 3.
    Jacobs SK, Wilson DJ, Kornblith PL (1986) Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J Neurosurg 64:743–749PubMedCrossRefGoogle Scholar
  4. 4.
    Lillehei KO, Mitchell DHM, Johnson ST, McCleary EL, Kruse CA (1991) Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28:16–23PubMedCrossRefGoogle Scholar
  5. 5.
    Merchant RE, Merchant LH, Cook HS, McVicar DW, Young HF (1988) Intralesional infusion of lymphokine-activated killer cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23:725–732PubMedCrossRefGoogle Scholar
  6. 6.
    Yoshida S, Tanaka R, Tahai N, Ono K (1990) Adoptice immunotherapy with LAK cells and interleukin-2 in treatment of recurrent malignant gliomas. Current Therapeutic Research 47:654–664Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • F. Weber
  • A. Klein-Struckmeyer
  • J. Menzel
  • U. Pohl
    • 1
  1. 1.Neurochirurgische Klinik der Städtischen Krankenanstalten Köln-MerheimGermany

Personalised recommendations